What is VICP's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 0.02B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for VICP?

P/E (TTM) is n/a and 52-week range is $0.11 to $1.77 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s VICP figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

Where is Vicapsys Life Sciences Inc based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cumming, Georgia, US, 32.1M shares outstanding, ISIN US92560A1060 when available from company profile and filing metadata.

Vicapsys Life Sciences Inc

$VICP

Health Care · Biotechnology

Run Scenarios

$0.55

+37.48%

Vicapsys Life Sciences Inc

$VICP

Health Care · Biotechnology

Run Scenarios

$0.55

+37.48%

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Vicapsys Life Sciences, Inc. is a development stage biotechnology company, which advances proprietary localized immune modulator. The company is headquartered in Cumming, Georgia and currently employs 2 full-time employees. The company went IPO on 2001-07-11. VICAPSYN is the Company’s product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field. The lead product candidate embodiment in transplantation therapy to treat Type 1 Diabetes (T1D) is an encapsulated human islet cell cluster that is intended to restore normal glucose control when implanted into the peritoneal cavity of a patient. The company also develops another product candidate line based on CXCL12 with the trade name of VYBRIN. The clinical applications of VYBRIN are being explored in several areas, including prevention of post-surgical adhesions in abdominal surgery, and others.

Employees

2

Website

vicapsys.com

IPO

2001-07-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (TTM)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

OTC MARKETS

ISIN

US92560A1060

Headquarters

Cumming, Georgia, US

Shares outstanding

32.1M

NAICS sector

Professional, Scientific, and Technical Services

Overview AI Summary Charts Financials Valuation

Profile

Read AI summary

Vicapsys Life Sciences, Inc. is a development stage biotechnology company, which advances proprietary localized immune modulator. The company is headquartered in Cumming, Georgia and currently employs 2 full-time employees. The company went IPO on 2001-07-11. VICAPSYN is the Company’s product line that is applied to transplantation therapies and related stem-cell applications in the transplantation field. The lead product candidate embodiment in transplantation therapy to treat Type 1 Diabetes (T1D) is an encapsulated human islet cell cluster that is intended to restore normal glucose control when implanted into the peritoneal cavity of a patient. The company also develops another product candidate line based on CXCL12 with the trade name of VYBRIN. The clinical applications of VYBRIN are being explored in several areas, including prevention of post-surgical adhesions in abdominal surgery, and others.

Employees

2

Website

vicapsys.com

IPO

2001-07-11

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)